PURPOSE: Patients with cancer often prefer to avoid time in the hospital; however, data are lacking on the prevalence and predictors of potentially avoidable readmissions (PARs) among those with advanced cancer. METHODS: We enrolled patients with advanced cancer from September 2, 2014, to November 21, 2014, who had an unplanned hospitalization and assessed their patient-reported symptom burden (Edmonton Symptom Assessment System) at the time of admission. For 1 year after enrollment, we reviewed patients' health records to determine the primary reason for every hospital readmission and we classified readmissions as PARs using adapted Graham's criteria. We examined predictors of PARs using nonlinear mixed-effects models with binomial distribution. RESULTS: We enrolled 200 (86.2%) of 232 patients who were approached. For these 200 patients, we reviewed 277 total hospital readmissions and identified 108 (39.0%) of these as PARs. The most common reasons for PARs were premature discharge from a prior hospitalization (30.6%) and failure of timely follow-up (28.7%). PAR hospitalizations were more likely than non-PAR hospitalizations to experience symptoms as the primary reason for admission (28.7% v 13.0%; P = .001). We found that married patients were less likely to experience PARs (odds ratio, 0.30; 95% CI, 0.15 to 0.57; P < .001) and that those with a higher physical symptom burden were more likely to experience PARs (odds ratio, 1.03; 95% CI, 1.01 to 1.05; P = .012). CONCLUSION: We observed that a substantial proportion of hospital readmissions are potentially avoidable and found that patients' symptom burdens predict PARs. These findings underscore the need to assess and address the symptom burden of hospitalized patients with advanced cancer in this highly symptomatic population.
PURPOSE:Patients with cancer often prefer to avoid time in the hospital; however, data are lacking on the prevalence and predictors of potentially avoidable readmissions (PARs) among those with advanced cancer. METHODS: We enrolled patients with advanced cancer from September 2, 2014, to November 21, 2014, who had an unplanned hospitalization and assessed their patient-reported symptom burden (Edmonton Symptom Assessment System) at the time of admission. For 1 year after enrollment, we reviewed patients' health records to determine the primary reason for every hospital readmission and we classified readmissions as PARs using adapted Graham's criteria. We examined predictors of PARs using nonlinear mixed-effects models with binomial distribution. RESULTS: We enrolled 200 (86.2%) of 232 patients who were approached. For these 200 patients, we reviewed 277 total hospital readmissions and identified 108 (39.0%) of these as PARs. The most common reasons for PARs were premature discharge from a prior hospitalization (30.6%) and failure of timely follow-up (28.7%). PAR hospitalizations were more likely than non-PAR hospitalizations to experience symptoms as the primary reason for admission (28.7% v 13.0%; P = .001). We found that married patients were less likely to experience PARs (odds ratio, 0.30; 95% CI, 0.15 to 0.57; P < .001) and that those with a higher physical symptom burden were more likely to experience PARs (odds ratio, 1.03; 95% CI, 1.01 to 1.05; P = .012). CONCLUSION: We observed that a substantial proportion of hospital readmissions are potentially avoidable and found that patients' symptom burdens predict PARs. These findings underscore the need to assess and address the symptom burden of hospitalized patients with advanced cancer in this highly symptomatic population.
Authors: Craig C Earle; Elyse R Park; Bonnie Lai; Jane C Weeks; John Z Ayanian; Susan Block Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Saskia C C M Teunissen; Wendy Wesker; Cas Kruitwagen; Hanneke C J M de Haes; Emile E Voest; Alexander de Graeff Journal: J Pain Symptom Manage Date: 2007-05-23 Impact factor: 3.612
Authors: Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag Journal: JAMA Date: 2017-07-11 Impact factor: 56.272
Authors: Daniel E Lage; Ryan D Nipp; Sara M D'Arpino; Samantha M Moran; P Connor Johnson; Risa L Wong; William F Pirl; Ephraim P Hochberg; Lara N Traeger; Vicki A Jackson; Barbara J Cashavelly; Holly S Martinson; Joseph A Greer; David P Ryan; Jennifer S Temel; Areej El-Jawahri Journal: J Clin Oncol Date: 2017-10-25 Impact factor: 44.544
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; John Z Ayanian; Susan D Block; Jane C Weeks Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544
Authors: Kelly L Graham; Andrew D Auerbach; Jeffrey L Schnipper; Scott A Flanders; Christopher S Kim; Edmondo J Robinson; Gregory W Ruhnke; Larissa R Thomas; Sunil Kripalani; Eduard E Vasilevskis; Grant S Fletcher; Neil J Sehgal; Peter K Lindenauer; Mark V Williams; Joshua P Metlay; Roger B Davis; Julius Yang; Edward R Marcantonio; Shoshana J Herzig Journal: Ann Intern Med Date: 2018-05-01 Impact factor: 25.391
Authors: Bobby Daly; Dmitriy Gorenshteyn; Kevin J Nicholas; Alice Zervoudakis; Stefania Sokolowski; Claire E Perry; Lior Gazit; Abigail Baldwin Medsker; Rori Salvaggio; Lynn Adams; Han Xiao; Yeneat O Chiu; Lauren L Katzen; Margarita Rozenshteyn; Diane L Reidy-Lagunes; Brett A Simon; Wendy Perchick; Isaac Wagner Journal: JCO Clin Cancer Inform Date: 2020-03
Authors: Ryan D Nipp; Eliza Shulman; Melissa Smith; Patricia M C Brown; P Connor Johnson; Eva Gaufberg; Charu Vyas; Carolyn L Qian; Isabel Neckermann; Shira B Hornstein; Mathew J Reynolds; Joseph Greer; Jennifer S Temel; Areej El-Jawahri Journal: BMC Cancer Date: 2022-04-09 Impact factor: 4.430
Authors: Lindsey A Herrel; Ziwei Zhu; Jennifer J Griggs; Deborah R Kaye; James M Dupree; Chandy S Ellimoottil; David C Miller Journal: JCO Oncol Pract Date: 2020-02-18
Authors: Melanie Potiaumpai; Shawna E Doerksen; Vernon M Chinchilli; Hongke Wu; Li Wang; Rachel Lintz; Kathryn H Schmitz Journal: Cancer Rep (Hoboken) Date: 2021-07-08